Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selecting drug combinations based on total equivalent dose (dose intensity)

R Simon1, E L Korn

  • 1Biometric Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

Journal of the National Cancer Institute
|September 19, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity.

ESMO open·2020
Same author

Interim monitoring for non-inferiority trials: minimizing patient exposure to inferior therapies.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Assessing treatment efficacy in the subset of responders in a randomized clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Response to comment on: 'evaluation of chemoresponse assays as predictive biomarkers'.

British journal of cancer·2015
Same author

Evaluation of chemoresponse assays as predictive markers.

British journal of cancer·2015
Same journal

Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates.

Journal of the National Cancer Institute·2026
Same journal

Breast cancer risk prediction with artificial intelligence: promise, calibration, and clinical readiness.

Journal of the National Cancer Institute·2026
Same journal

RE：Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.

Journal of the National Cancer Institute·2026
Same journal

Worsening frailty and declining quality of life in older survivors of non-metastatic breast cancer.

Journal of the National Cancer Institute·2026
Same journal

Longitudinal effects of comorbidities on brain structure and cognition in older breast cancer survivors.

Journal of the National Cancer Institute·2026
Same journal

Response to Wang et al. and Shen et al.

Journal of the National Cancer Institute·2026
See all related articles

This study presents a mathematical model to optimize combination chemotherapy regimens. It balances antitumor effects and drug toxicities to identify promising drug combinations for clinical trials.

Area of Science:

  • Mathematical Oncology
  • Pharmacology
  • Clinical Trial Design

Background:

  • Selecting optimal drug combinations for cancer therapy is complex due to numerous possibilities.
  • Balancing efficacy and toxicity is crucial for effective combination chemotherapy.

Purpose of the Study:

  • To develop a mathematical model for selecting cytotoxic drug combinations and dosages.
  • To maximize antitumor effect while managing combined organ-specific toxicities.

Main Methods:

  • Utilized a mathematical modeling approach.
  • Incorporated single-agent antitumor activities and maximum tolerated doses (MTDs).
  • Optimized regimens based on predicted antitumor effect and toxicity constraints.

Main Results:

Related Experiment Videos

  • The model identifies combination regimens that maximize a defined measure of antitumor effect.
  • The approach does not require steep dose-response curves or assume maximal dose intensity is always optimal.
  • The model provides a rational method for selecting combinations for further investigation.

Conclusions:

  • The described mathematical model offers a systematic approach to optimizing combination chemotherapy.
  • This method can guide the selection of promising regimens for prospective clinical trials.
  • Further validation through randomized clinical trials is necessary to confirm superiority over standard treatments.